Browse > Article
http://dx.doi.org/10.4046/trd.2020.0088

Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases  

Deshmukh, Kartik (Fuqua School of Business, Duke University)
Khanna, Arjun (Department of Pulmonary Medicine, Yashoda Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.84, no.1, 2021 , pp. 35-45 More about this Journal
Abstract
Globally, cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are the leading causes of the non-communicable disease burden. Overlapping symptoms such as breathing difficulty and fatigue, with a lack of awareness about COPD among physicians, are key reasons for under-diagnosis and resulting sub-optimal care relative to COPD. Much has been published in the past on the pathogenesis and implications of cardiovascular comorbidities in COPD. However, a comprehensive review of the prevalence and impact of COPD management in commonly encountered cardiac diseases is lacking. The purpose of this study was to summarize the current knowledge regarding the prevalence of COPD in heart failure, ischemic heart disease, and atrial fibrillation. We also discuss the real-life clinical presentation and practical implications of managing COPD in cardiac diseases. We searched PubMed, Scopus, EMBASE, and Google Scholar for studies published 1981-May 2020 reporting the prevalence of COPD in the three specified cardiac diseases. COPD has high prevalence in heart failure, atrial fibrillation, and ischemic heart disease. Despite this, COPD remains under-diagnosed and under-managed in the majority of patients with cardiac diseases. The clinical implications of the diagnosis of COPD in cardiac disease includes the recognition of hyperinflation (a treatable trait), implementation of acute exacerbations of COPD (AECOPD) prevention strategies, and reducing the risk of overuse of diuretics. The pharmacological agents for the management of COPD have shown a beneficial effect on cardiac functions and mortality. The appropriate management of COPD improves the cardiovascular outcomes by reducing hyperinflation and preventing AECOPD, thus reducing the risk of mortality, improving exercise tolerance, and quality of life.
Keywords
Chronic Obstructive Pulmonary Disease; Heart Failure; Atrial Fibrillation; Ischemic Heart Disease; Hyperinflation; Cardiovascular Diseases; Spirometry; COPD-CVD;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012;126:65-75.   DOI
2 Travers J, Laveneziana P, Webb KA, Kesten S, O'Donnell DE. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 2007;101:2017-24.   DOI
3 Tuleta I, Farrag T, Busse L, Pizarro C, Schaefer C, Pingel S, et al. High prevalence of COPD in atherosclerosis patients. Int J Chron Obstruct Pulmon Dis 2017;12:3047-53.   DOI
4 Dalsgaard M, Plesner LL, Schou M, Kjoller E, Vestbo J, Iversen K. Prevalence of airflow obstruction in patients with stable systolic heart failure. BMC Pulm Med 2017;17:6.   DOI
5 Rennard SI. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. Proc Am Thorac Soc 2005;2:94-100.   DOI
6 Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49:171-80.   DOI
7 Gale NS, Duckers JM, Enright S, Cockcroft JR, Shale DJ, Bolton CE. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med 2011;11:20.   DOI
8 Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease: an Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201:e56-69.   DOI
9 Stringer W, Porszasz J, Von Plato M, Khosrovi-Eghbal A, Zopey M, Cao M, et al. A randomized trial to determine th-e effect of glycopyrrolate/formoterol on exercise tolerance in COPD: influence of dynamic hyperinflation and dead space ventilation. Eur Respir J 2019;54:OA259.
10 Vogel-Claussen J, Schonfeld CO, Kaireit TF, Voskrebenzev A, Czerner CP, Renne J, et al. Effect of indacaterol/glycopyrronium on pulmonary perfusion and ventilation in hyperinflated patients with chronic obstructive pulmonary disease (CLAIM): a double-blind, randomized, crossover trial. Am J Respir Crit Care Med 2019;199:1086-96.   DOI
11 Minasian AG, van den Elshout FJ, Dekhuijzen PR, Vos PJ, Willems FF, van den Bergh PJ, et al. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med 2014;2:12.   DOI
12 Huang WM, Cheng HM, Shiao TH, Chen CH, Yu WC, Sung SH. The role pulmonary function test in patients with heart failure with preserved ejection fraction: looking beyond chronic obstruction pulmonary disease. J Am Coll Cardiol 2017;69(11 Suppl):878.   DOI
13 Arnaudis B, Lairez O, Escamilla R, Fouilloux A, Fournier P, Monteil B, et al. Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol 2012;101:717-26.   DOI
14 Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27:180057.   DOI
15 Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 2018;6:368-78.   DOI
16 Stone IS, Barnes NC, James WY, Midwinter D, Boubertakh R, Follows R, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2016;193:717-26.   DOI
17 Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020;201:1508-16.   DOI
18 Divo MJ, DePietro MR, Horton JR, Maguire CA, Celli BR. Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. Respir Res 2020;21:26.   DOI
19 Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc 2016;5:e002197.   DOI
20 Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, et al. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation 2013;127:1503-11.   DOI
21 Watz H. Chronic obstructive pulmonary disease: when pulmonologists do something good for the heart. Am J Respir Crit Care Med 2016;193:703-4.   DOI
22 Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines-heart failure registry. Circ Heart Fail 2018;11:e004646.   DOI
23 Han Y, Heo Y, Hong Y, Kwon SO, Kim WJ. Correlation between physical activity and lung function in dusty areas: results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) cohort. Tuberc Respir Dis 2019;82:311-8.   DOI
24 Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998-1005.   DOI
25 Kamalesh M, Subramanian U, Sawada S, Eckert G, Temkit M, Tierney W. Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail 2006;8:404-8.   DOI
26 Di Lenarda A, Scherillo M, Maggioni AP, Acquarone N, Ambrosio GB, Annicchiarico M, et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds: the TEMISTOCLE study. Am Heart J 2003;146:E12.
27 Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-9.   DOI
28 Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP. et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;198:1130-9.   DOI
29 Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-7.   DOI
30 Park HJ, Kim SH, Kim HC, Lee BY, Lee SW, Lee JS, et al. Utility of computed tomography in a differential diagnosis for the patients with an initial diagnosis of chronic obstructive pulmonary disease exacerbation. Tuberc Respir Dis 2019;82:234-41.   DOI
31 Navarro A, Lapuente AM, Pareja J, Barrera A, Yun S, De La Sierra A, et al. Prevalence and underdiagnosis of COPD in patients with ischemic heart disease demonstrated by coronary angiography: prognostic implications. Eur Respir J 2015;46:PA4807.   DOI
32 Takase H, Machii M, Nonaka D, Sugiura T, Yamashita S, Ohte N, et al. Does airflow limitation predict the future hypertension in the normotensive general population? Eur Heart J 2017;38(Suppl 1):ehx504.P4426.
33 Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009;179:35-40.   DOI
34 Muralimohan BV, Ekbote G, Tousheed SZ, Ramanjenaya R. Prevalence of COPD in vascular diseases. Eur Respir J 2015;46:PA1131.   DOI
35 Soriano JB, Rigo F, Guerrero D, Yanez A, Forteza JF, Frontera G, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010;137:333-40.   DOI
36 Franssen FM, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med 2016;194:568-76.   DOI
37 Mahendra M, S SK, Desai N, Bs J, Pa M. Evaluation for airway obstruction in adult patients with stable ischemic heart disease. Indian Heart J 2018;70:266-71.   DOI
38 Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J 2000;27:257-67.
39 Rodriguez-Manero M, Lopez-Pardo E, Cordero A, RuanoRavina A, Novo-Platas J, Pereira-Vazquez M, et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis 2019;14:371-80.   DOI
40 Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014;114:272-7.   DOI
41 Adam O, Ukena C, Bohm M, Neuberger HR. Bidirectional ventricular tachycardia in a patient with exacerbation of chronic obstructive pulmonary disease. Clin Res Cardiol 2012;101:851-2.   DOI
42 Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281-93.   DOI
43 Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217-27.   DOI
44 Nojiri T, Yamamoto K, Maeda H, Takeuchi Y, Funakoshi Y, Maekura R, et al. Effects of inhaled tiotropium on left ventricular diastolic function in chronic obstructive pulmonary disease patients after pulmonary resection. Ann Thorac Cardiovasc Surg 2012;18:206-11.   DOI
45 Guder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep 2014;11:337-46.   DOI
46 Mihailichenko D, Pertseva T. COPD as undetected cause of dyspnea in patients admitted with ischaemic heart disease (IHD). Eur Respir J 2014;44:P3638.
47 Wakabayashi K, Gonzalez MA, Delhaye C, Ben-Dor I, Maluenda G, Collins SD, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010;106:305-9.   DOI
48 Hamrah MS, Suzuki S, Ishii H, Shibata Y, Tatami Y, Osugi N, et al. Impact of airflow limitation on carotid atherosclerosis in coronary artery disease patients. Respiration 2015;89:322-8.   DOI
49 Global Initiative for Chronic Obstructive Lung Disease [Internet]. Fontana: Global Initiative for Chronic Obstructive Lung Disease; 2020 [cited 2020 Aug 10]. Available from: https://goldcopd.org/.
50 Kchaou K, Kammoun R, Chaabouni M, Trabelsi H, Triki L, Kammoun I, et al. Impact of concomitant cardiovascular diseases on functional status and quality of life of patients with chronic obstructive pulmonary disease. Eur Respir J 2019;54:PA4489.
51 Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med 2018;137:14-22.   DOI
52 Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817-26.   DOI
53 Ulrik CS, Lokke A, Dahl R, Dollerup J, Hansen G, Cording PH, et al. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis 2011;6:123-7.
54 Bektas S, Franssen FM, van Empel V, Uszko-Lencer N, Boyne J, Knackstedt C, et al. Impact of airflow limitation in chronic heart failure. Neth Heart J 2017;25:335-42.   DOI
55 Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail 2012;18:637-44.   DOI
56 Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 2014;18:2908-17.
57 Cao J, Halloran K, Cheng J, Passick M, Ngai N. Adverse cardiac and pulmonary vascular change in patients with subclinical and clinical COPD. Circulation 2014;130(Suppl 2):A15873.
58 Ragaisiene G, Kibarskyte R, Gauronskaite R, Giedraityte M, Dapsauskaite A, Kasiulevicius V, et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip Respir Med 2019;14:28.   DOI
59 Ozben B, Eryuksel E, Tanrikulu AM, Papila N, Ozyigit T, Celikel T, et al. Acute exacerbation impairs right ventricular function in COPD patients. Hellenic J Cardiol 2015;56:324-31.
60 Tabara Y, Muro S, Takahashi Y, Setoh K, Kawaguchi T, Terao C, et al. Airflow limitation in smokers is associated with arterial stiffness: the Nagahama Study. Atherosclerosis 2014;232:59-64.   DOI
61 Cuthbert JJ, Kearsley JW, Kazmi S, Kallvikbakka-Bennett A, Weston J, Davis J, et al. The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol 2019;108:185-93.   DOI
62 Zaas D, Wise R, Wiener C; Longcope Spirometry Invetigation Team. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. Chest 2004;125:106-11.   DOI
63 Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006;51:1120-4.
64 O'Donnell DE, Gebke KB. Activity restriction in mild COPD: a challenging clinical problem. Int J Chron Obstruct Pulmon Dis 2014;9:577-88.   DOI
65 Minasian A, Dekhuijzen R, Van den Elshout F, Vos P, Willems F, Van den Bergh P, et al. COPD prevalence in chronic heart failure. Eur Respir J 2011;38:1019.   DOI
66 Bertens LC, Reitsma JB, van Mourik Y, Lammers JW, Moons KG, Hoes AW, et al. COPD detected with screening: impact on patient management and prognosis. Eur Respir J 2014;44:1571-8.   DOI
67 Schroeder EB, Welch VL, Evans GW, Heiss G. Impaired lung function and subclinical atherosclerosis. The ARIC Study. Atherosclerosis 2005;180:367-73.   DOI
68 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-59.   DOI
69 Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, et al. Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis 2018;81:261-73.   DOI
70 Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12:1753465817750524.
71 Heredia D, Renner-Carmona JL, Rosales L, Romelus A, Mendes ES, Campos M. Prevalence and Underdiagnosis of COPD: a comparison between primary care and cardiology clinics. Am J Respir Crit Care Med 2012;185:A2308.
72 Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail 2006;8:706-11.   DOI
73 Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol 1987;17:207-9.   DOI
74 Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005;91:907-13.   DOI
75 Hemat A, Muller P, Jung C, Kruger S, Keymel S. Increased risk of atrial fibrillation in patients with acute exacerbation of chronic obstructive pulmonary disease and sinus rhythm. Eur Respir J 2018;52:PA745.
76 Kolacinska-Flont M, Drozdz J, Zielinska M, Kuprys-Lipinska I, Kuna P. Asthma and COPD in patients with coronary artery disease: the unmet demands. Eur Respir J 2016;48:OA256.
77 Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001;87:413-9.   DOI
78 Shafuddin E, Chang CL, Cooray M, Tuffery CM, Hopping SJ, Sullivan GD, et al. Changes in biomarkers of cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Respir Med 2018;145:192-9.   DOI
79 Goto T, Shimada YJ, Faridi MK, Camargo CA Jr, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med 2018;33:1461-8.   DOI
80 Rothnie KJ, Connell O, Mullerova H, Smeeth L, Pearce N, Douglas I, et al. Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2018;15:935-46.   DOI
81 Portegies ML, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH, et al. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam Study. Am J Respir Crit Care Med 2016;193:251-8.   DOI
82 Labaki WW, Han MK. Improving detection of early chronic obstructive pulmonary disease. Ann Am Thorac Soc 2018;15(Suppl 4):S243-8.   DOI
83 Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
84 Joo H, Han D, Lee JH, Rhee CK. Incidence of adverse effects and discontinuation rate between patients receiving 250 micrograms and 500 micrograms of roflumilast: a comparative study. Tuberc Respir Dis 2018;81:299-304.   DOI
85 White WB, Cooke GE, Kowey PR, Calverley PM, Bredenbroker D, Goehring UM, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013;144:758-65.   DOI
86 Evans RA. Developing the model of pulmonary rehabilitation for chronic heart failure. Chron Respir Dis 2011;8:259-69.   DOI
87 Arnold MT, Dolezal BA, Cooper CB. Pulmonary rehabilitation for chronic obstructive pulmonary disease: highly effective but often overlooked. Tuberc Respir Dis 2020;83:257-67.   DOI
88 Giannuzzi P, Temporelli PL, Corra U, Tavazzi L; ELVD-CHF Study Group. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 2003;108:554-9.   DOI